Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
Abroad (travel likely)Recruiting
Conditions
Pathological Complete Remission · Objective Response Rate · Immune-related Adverse Events · Quality of Life
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The Second Qilu Hospital of Shandong University, Jinan, China
Study leads
Yunpeng Zhao, doctor
Study Director
The Second Qilu Hospital of Shandong University